短期課程
1:00 - 4:00 Concurrent Afternoon courses
SC1 Identification, Characterization and Targeting of Cancer Stem Cells
A session that examines new tools and new targets, treatment strategies, cancer stem cell lines in drug discovery and development, new therapeutic agents that reduce tumor initiating cell frequency, and defining a cancer stem cell hierarchy for effective targeting.
Robert Hollingsworth, Ph.D., Director, Cancer Biology, MedImmune, Inc.
Norman J. Maitland, Ph.D., CSO, Procure Therapeutics Ltd.
Jennie P. Mather, Ph.D., Senior Vice President, Stem Cell Research, Macrogenics, Inc.
Timothy Hoey, Ph.D., Senior Vice President, Cancer Biology, OncoMed Pharmaceuticals, Inc.
Albert J. Wong, M.D., Professor, Cancer Biology and Neurosurgery, Stanford University Medical Center
Click here for a more detailed agenda
SC2 Roadmap for Accelerating Commercialization of Molecular Diagnostics
This short course is focused on development of molecular diagnostics as they make their way from biomarker discovery and initial proof of clinical performance through to commercial launch, partnership delivery and market development.
William Cook, M.B.A., Principal, Strategy and Business Development, Clinical Diagnostics, WECA
Patrick F. Terry, Principal, Pricing & Market Access Practice, Scientia Advisors
Rina Wolf, Vice President, Commercialization Strategies, Consulting & Industry Affairs, Xifen
Click here for a more detailed agenda
SC3 Understanding EMT: Mechanisms and Metastasis to MET
This course will provide a framework of the underlying molecular mechanisms of EMT while addressing stem cells, and cancer progression, cMET and their activity as anti-metastasis agents, and the Mesenchymal-Epethelial Transition (MET) as an essential process for tumor re-initiation, colonization, and metastasis.
Sendurai A. Mani, Ph.D., Assistant Professor, Department of Molecular Pathology; Co-Director, Metastasis Research Center, MD Anderson Cancer Center
George Vande Woude, Ph.D., Director & Distinguished Scientific Investigator, Van Andel Institute
Fredika M. Robertson, Ph.D., Professor, Department of Experimental Therapeutics, Center for Targeted Therapy, Translational Therapeutics Laboratory, Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, MD Anderson Cancer Center
Click here for a more detailed agenda
This course will describe several real applications, with case studies, of the principles of biological networks, chemical promiscuity, and network pharmacology that have generated compounds, for example in cancer therapy and antibiotics, with potent efficacy and acceptable safety profiles.
Malcolm Young, Ph.D., CEO, e-Therapeutics
Jake Chen, Ph.D., Associate Professor, Informatics, Indiana University
Click here for a more detailed agenda
SC5 Next-Generation Sequencing in the Cloud Era
The nature of infrastructure cloud platforms makes them perfect for tools designed to automatically provision, configure and deploy systems, servers, clusters and complex scientific pipelines to support sequencing analysis. Data movement, application scaling, security and emerging patterns in cloud architectures will be explored.
Adam Kraut, Scientific Consultant, BioTeam, Inc.
Jacob Glanville, Research Informatics Developer, BBC Informatics, Pfizer Global R&D
SC6 Marketing and Sales: Science Training 101
This course examines basic biology and genetics concepts for life sciences marketing and sales professionals. Topics covered include: cell structure, inheritance and replication, gene expression and epigenetics, current and next-gen sequencing technologies and their impact on discovery and therapy, and personalized medicine.
Ellen Martin, Partner, Kureczka/Martin Associates
Joan Kureczka, Partner, Kureczka/Martin Associates
SC7 Latest Advances in Molecular Pathology, Part I (Basic)
This course is designed to educate practicing pathologists on the current molecular diagnostics technologies. The course is created in collaboration with Cambridge Healthtech Institute and the College of American Pathologists.
Athena Cherry, Ph.D., Director, Cytogenetics Laboratory, Professor, Pathology and Pediatrics, Stanford Comprehensive Cancer Center
Iris Schrijver, M.D., Associate Professor of Pathology and (by courtesy) Pediatrics, Stanford University School of Medicine Pathology
Michael Roehrl, M.D., Assistant Professor of Pathology and Laboratory Medicine, Pathology and Laboratory Medicine, Boston Medical Center
Click here for a more detailed agenda
SC8 Best Practices in Translational Informatics
This course will explore real world solutions currently in place in pharma, research institutions, and academia. We will discuss tools for enabling better and faster clinical research and informatics solutions that link data from the clinic with cutting edge research.
Kevin Davies, Ph.D., Editor-in-Chief, Bio-IT World
Joshua Snyder, Novartis Institutes for BioMedical Research
Sean Ekins, Collaborative Drug Discovery
Sanjay Joshi, Solutions Architect, Life Sciences, Isilon Systems
SC9 Pharmacology and Drug Discovery in the Allosteric World
High-throughput screening is changing the type of molecules found. This course will familiarize researchers with the tools needed to exploit this area of new drug discovery through discussion of allosteric molecules, detection of allosterism, and quantifying allosterism for lead optimization.
Terry Kenakin, Ph.D., Professor, Department of Pharmacology, University of North Carolina
Click here for a more detailed agenda
SC10 Digital PCR Applications and Advances
Digital PCR is poised to make a significant impact in the diagnostics field. This course will address the differences between digital PCR and other PCR techniques, copy number variation, detection of gene expression at the single molecule level and mutation detection.
Carl Lars Hansen, Ph.D., Assistant Professor, Center for High-Throughput Biology, Department of Physics and Astronomy, University of British Columbia
Jason H. Bielas, Ph.D., Assistant Member, Molecular Diagnostics Program, Fred Hutchinson Cancer Research Center (FHCRC); Affiliate Assistant Professorship, Department of Pathology, University of Washington
Ben Ho Park, M.D., Ph.D., Associate Professor, Oncology, Breast Cancer Research Program; Associate Director, Hematology/Oncology Fellowship Training Program, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Click here for a more detailed agenda
SC11 CTCs from Bench to Bed: Streamlining from Research to Clinical Practice
This course will focus on validation of CTC research data for clinical practice, correlations between CTCs, diagnosis and responses to therapy.
Marek Malecki, M.D., Ph.D., Associate Professor of Genetics, Genomics, and Gene Therapy; Director, Biotechnology Program, Western University of Health Sciences
Additional Instructors to be Announced
SC12 First-in-Human Study and Risk Mitigation Strategy for Biologics
This course will review the basic concepts and study designs for early drug development including Phase I First-in-Human (FIH) Single Ascending Dose (SAD), Food Effect (EF), Multiple Ascending Dose (MAD) and Phase IIa Proof-of-Concept studies, biologic FIH starting dose estimation from No Observed Adverse, Effect Level (NOAEL) to Minimum Anticipated Biological Effect level (MABEL) approach.
Sean Zhang, M.D., Medical Director, Discovery Medicine and Clinical Pharmacology, Bristol-Myers Squibb
Click here for a more detailed agenda
SC13 Scientists: Business Training 101
This course examines basic business concepts and terminology for scientists. Topics covered include: finance, marketing, positioning and selling your business, presenting persuasively to venture capitalists, and reaching your target audience with 21st century communications. The course will feature interactive discussions and video presentations.
Ellen Martin, Partner, Kureczka/Martin Associates
Joan Kureczka, Partner, Kureczka/Martin Associates
SC14 Adaptive Oncology Clinical Trials
Most advanced adaptive designs have been developed for the oncology clinical trials. This course will review these designs with specific focus on continual reassessment methods, seamless Phase I/II designs, Bayesian response adaptive designs, seamless Phase II/III designs and population enrichment designs.
Vlad Dragalin, Senior Vice President, Innovation Center, Aptiv Solutions
Click here for a more detailed agenda
SC15 Latest Advances in Molecular Pathology, Part II (Advanced)
This course is designed to educate practicing pathologists on advanced and future applications of molecular diagnostics technologies. The course is created in collaboration with Cambridge Healthtech Institute and the College of American Pathologists.
Wayne Grody, M.D., Ph.D., Professor, Departments of Pathology & Laboratory Medicine, Pediatrics, and Human Genetics, University of California Los Angeles School of Medicine
Nazneen Aziz, Ph.D., Director, Molecular Medicine, College of American Pathologists
Jeffrey A. Kant, M.D., Ph.D., Director, Division of Molecular Diagnostics, University of Pittsburgh Medical Center Health System
Karl Voelkerding, M.D., Associate Professor, Pathology, University of Utah; Medical Director, Advanced Technology and Bioinformatics, ARUP Laboratories
Click here for a more detailed agenda
SC16 Ontologies for the Bio-Science Industry: Development & Use
There is a growing trend in the life sciences to move away from traditional terminology-based ontologies. Ontological Realism strives to develop ontologies that are more stable and able to support automated reasoning using a semantics more powerful than semantic web languages.
Werner Ceusters, M.D., Professor, Department of Psychiatry; Director, Ontology Research Group, NYS Center of Excellence in Bioinformatics & Life Sciences
Click here for a more detailed agenda
SC17 Mastering Physicochemical Properties-Based Analysis to Deliver Improved Drug Candidates
This interactive workshop will enable participants to learn the keys to mastering an integrated approach to improve medicinal chemistry lead optimization that yields high quality clinical candidates. Multiple real-life case studies will be used to illustrate the effectiveness of this approach.
Martin P. Edwards, Vice President, Discovery Chemistry, Pfizer San Diego
SC18 Regulatory Approval of a Therapeutic & Companion Diagnostic: Nuts & Bolts
Overview of the requirements and processes for coordinated NDA/PMA or BLA/PMA submissions leading to simultaneous approvals of a therapeutic and companion diagnostic; from working with CDER, CBER and CDRH to labeling considerations, as well as an overview of the evolving Rx/Dx regulatory landscape.
Nancy Gerber, Associate Director, Regulatory Affairs, Genentech
Erling Thor Donnelly, Ph.D., R.A.C., Director, Worldwide Regulatory Strategy, Pfizer, Inc.
Pamela L. Swatkowski, Director, Regulatory Affairs, Abbott Molecular, Inc.
